Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

opicapone

- PMLiVE

First migraine prevention drug to hit European market

European Commission green lights Novartis’ Aimovig

- PMLiVE

Alnylam’s amyloidosis drug heads latest crop of CHMP approvals

Three new biosimilars also gets the green light

- PMLiVE

GSK: we won’t be splitting up any time soon

Walmsley scotches rumours of a consumer health spin-off

- PMLiVE

Daily Brief: GSK unveils R&D plan, Keytruda OK’d for lymphoma by NICE

News from pharma, biotech and healthcare

Celgene building

Celgene’s Revlimid gets a win in late-stage lymphoma

Patients on Revlimid and Roche’s Rituxan saw boosted PFS rates

Roche Basel Switzerland

Roche’s Tamiflu successor hits the mark in complicated flu

Baloxavir marboxil met its primary objective and cut flu-related complications

Roche Basel Switzerland

Roche keeps Venclexta train rolling with new leukaemia filing

The drug could treat AML patients who are ineligible for chemotherapy

- PMLiVE

NHS England says yes to Roche’s Hemlibra

But stalls on funding for Actelion's Uptravi

Genetic testing: nothing to write home about?

An issue of health literary and health motivation?

- PMLiVE

Roche reshuffles its executive committee, again

Sophie Kornowski-Bonnet joins Reed and heads for the exit

Roche Basel Switzerland

Roche agrees $2.4bn takeover of genomics player Foundation

Offers a 29% premium on the Foundation’s recent share price

- PMLiVE

AbbVie, Roche get FDA OK for broader use of Venclexta

The drug is tipped to become a $2.5bn product by 2024

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links